Skip to main content

ADVERTISEMENT

Jessica Madera, MD

03/01/2019
10/08/2020
Objectives: Aripiprazole once-monthly 400 mg (AOM 400) is a long-acting injectable formulation of aripiprazole licensed in the US, Canada and Australia for maintenance treatment of adults...
10/08/2020
Introduction: Sexual dysfunction is a common side effect of antipsychotic treatment and may contribute to non-adherence. In the QUALIFY study (NCT01795547) the effectiveness of aripiprazo...
11/22/2019
Objective: To assess the efficacy and safety of Aripiprazole Once-Monthly (AOM 400) in preventing recurrence of mood episodes in patients with rapid and non-rapid cycling Bipolar I disord...
03/01/2019
Background: The established role of oral aripiprazole in the treatment of Bipolar I disorder (BP-I) and the potential for a long-acting injectable formulation to improve adherence and pre...
03/01/2019